| pubmed-article:17227902 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0278689 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0006610 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1423594 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C2346918 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1538046 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:17227902 | lifeskim:mentions | umls-concept:C0443172 | lld:lifeskim |
| pubmed-article:17227902 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17227902 | pubmed:dateCreated | 2007-1-17 | lld:pubmed |
| pubmed-article:17227902 | pubmed:abstractText | To examine early changes in CA125 relative to objective response in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD) or topotecan and to compare the CA125 trends between the two chemotherapeutics. | lld:pubmed |
| pubmed-article:17227902 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17227902 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17227902 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17227902 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:17227902 | pubmed:issn | 1083-7159 | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:ColemanRobert... | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:HerzogThomas... | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:RackoffWayneW | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:BarterJamesJ | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:SunStevenS | lld:pubmed |
| pubmed-article:17227902 | pubmed:author | pubmed-author:GordonAlanA | lld:pubmed |
| pubmed-article:17227902 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17227902 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:17227902 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17227902 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17227902 | pubmed:pagination | 72-8 | lld:pubmed |
| pubmed-article:17227902 | pubmed:dateRevised | 2007-5-15 | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:meshHeading | pubmed-meshheading:17227902... | lld:pubmed |
| pubmed-article:17227902 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17227902 | pubmed:articleTitle | Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. | lld:pubmed |
| pubmed-article:17227902 | pubmed:affiliation | The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA. rcoleman@mdanderson.org | lld:pubmed |
| pubmed-article:17227902 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17227902 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17227902 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17227902 | lld:pubmed |
